



ASIC CONSENT FOR RESIGNATION OF ERNST & YOUNG AS AUDITOR

2 November 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announces that the Australian Securities and Investment Commission (ASIC) has consented to the resignation of Ernst & Young (EY) as auditor, to take effect at the close of the Annual General Meeting of the Company to be held on 30 November 2023.

Therefore, the proposed resolution to appoint BDO Audit Pty Ltd as the new auditor of the Company will be put to the meeting for approval by the shareholders as detailed in Item 5 of the Notice of the Annual General Meeting.

The reason for the change in auditor is to give effect to the result of a competitive audit tender process conducted during 2023.

For further information contact:

Australia:

Craig Haskins

+61 421 029 843

ir@maynepharma.com

USA:

Lisa M. Wilson

+1 917-543-9932

ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.